May 14th 2025
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
Watch the series now!
Dr Kerin Adelson on Changes in Care Coordination Precipitated by OCM
Cancer Does Not Stop for COVID-19, but Reform Becomes a Challenge
Counties Experiencing Persistent Poverty Have Higher Cancer Mortality Rates
Dr Kashyap Patel Discusses COVID-19 Implications for PCOC® 2020